News

Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.

However

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults

Over the past decade, few stocks have been as much of a disappointment as AT&T (NYSE: T). As you can see from the chart below, the stock price has fallen 41% during that time, even though it's

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

On June 26, FibroGen's (NASDAQ: FGEN) lead program, pamrevlumab, reported poor late-stage clinical trial results for the second time in a month, sending its stock barreling downward to the tune of

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

MicroVision (NASDAQ: MVIS) closed the work week in style, with its stock price rising by over 17% on Friday. That was a far better performance than the S&P 500 index's 1.2% increase. Investors

Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data

Things have not quite gone as hoped lately for shares of Sarepta Therapeutics (NASDAQ: SRPT). Recently, the biotech received approval from the Food and Drug Administration (FDA) for its cutting-edge

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of

Shares of CorMedix (NASDAQ: CRMD) were down more than 21% as of noon ET on Thursday. The shares fell after the company announced a stock sale. The healthcare stock is down more than 5% so far this

If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking. The tech sector has been attracting more attention of late due to the hype around artificial

What do CRISPR Therapeutics (NASDAQ: CRSP), Bluebird Bio (NASDAQ: BLUE), Editas Medicine (NASDAQ: EDIT), and Intellia Therapeutics (NASDAQ: NTLA) all have in common? If you said, "They're biotechs

Last year, inflation rose at its fastest pace in over 40 years. The annual inflation rate, as measured by the year-over-year change in the Consumer Price Index (CPI), peaked at 9.1% in July 2022 and

Viking Therapeutics (NASDAQ: VKTX) and Nano-X Imaging (NASDAQ: NNOX) are two small-cap healthcare companies with lots of potential, but their shares come with some hefty risks. They've also both

There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.

Artificial intelligence (AI) is an umbrella term for the use of computer vision, machine learning, and natural language processing to empower machines to do things that usually require human

Whether you're saving for retirement, want to set aside money for travel, or just want to give yourself a raise, dividend stocks can help give you some extra income to accomplish those goals. Plus

It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA).

According to a media report from a leading financial news

Shares of Axsome Therapeutics (NASDAQ: AXSM) were down more than 10% as of 3:45 p.m. ET Wednesday after the company announced it is offering 3 million shares at $75 each in a stock sale worth $225